Skin Conditions that Mimic Tinea Pedis
Transcription
Skin Conditions that Mimic Tinea Pedis
Skin Conditions that Mimic Tinea Pedis Marti Jill Rothe, M.D. Associate Professor of Dermatology UConn Health Center Conditions that Mimic Tinea Pedis • Allergic Contact Dermatitis • Dyshidrosis/Pompholyx • Palmoplantar Psoriasis All of these conditions can be complicated by secondary tinea pedis and unguium Allergic Contact Dermatitis • A warm, moist environment and occlusion within the shoe potentiates development of dermatitis • Areas of foot in contact with the culprit allergen are usually affected but spreading of the skin reaction beyond the areas of contact is common • Usually contact dermatitis spares toe webs, flexural creases of the toes, and instep • Usually contact dermatitis is symmetrical but may affect one foot to a greater degree • Id reactions with vesicles on hands, papulovesicles on trunk and extremities, nummular plaques on trunk and extremities may be evident Allergic Contact Dermatitis to Shoes Allergic contact dermatitis to shoes spares the toe webs and plantar arch but affects the other aspects of the plantar foot and often the dorsal foot under the tongue of the shoe. Nederost Allergic Contact Dermatitis with Id Reaction Allergic Contact Dermatitis with Id Reaction Most Common Sources of Culprit Allergens • • • • Shoes Socks and stockings Medicaments Vehicles, preservatives, fragrances in topical medications and moisturizers • Metals Allergic Contact Dermatitis: Patch Testing Allergic Contact Dermatitis: Patch Testing Most Common Culprit Allergens Para‐tertiary butylphenol formaldehyde resin: – Additive in rubber glues – Found as component of neoprene adhesives used to attach shoe linings and insoles Allergic Contact Dermatitis to Shoe Glue Oztas et al: Contact Dermatitis 2007;56:294‐5 Most Common Culprit Allergens Rubber allergens: – Carba mix, thiuram mix, MBT, mercapto mix, mixed dialkyl thioureas, black rubber mix – May be present in outer sole, insoles, tongues, outer upper toe in athletic shoes – May migrate to other parts of shoe when shoe becomes wet Allergic Contact Dermatitis to Rubber Nederost: Dermatologic Clinics 2009;27:281‐7 Purpuric Dermatitis to Black Rubber Mix • Purpuric allergic contact dermatitis is rare • Most commonly implicated allergens: rubber chemicals and textile dyes • Less common allergens: chromium, epoxy resins, and formaldehyde resins • Irritant purpuric contact dermatitis has been reported secondary to topical EMLA cream, benzoyl peroxide, and sap of Agave americana Verma et al: Contact Dermatitis 2007;56:362‐4 Most Common Culprit Allergens Chromium: – Tanning agent for leather – Newer manufacturing processes give better fixation of chromium and make it less likely for chromium to be leached from shoes due to perspiration Allergic Contact Dermatitis to Textile Dye in Socks Opie et al: Contact Dermatitis 2004;297‐303 Allergic Contact Dermatitis to Medicaments Patient had positive patch test reactions to lanolin, econazole nitrate, and iodopropynyl butyl carbamate Nederost Consider Patch Testing to the Patient’s Shoes • Use very thin samples to avoid pressure effects • Soak samples in water for 15 minutes before application • Leave in place for 4‐5 days rather than the usual 2 days Allergic Contact Dermatitis: Is it from dimethylfumarate? My patient reported developing rash on foot shortly after he began wearing new sandals manufactured in China. Dimethylfumarate is present in a powder used in sachets which are placed in sofas and shoe boxes to protect from mold. The chemical evaporates and impregnates the products. There have been numerous reports of allergic contact dermatitis secondary to dimethylfumarate in products imported from China. Management of Shoe Dermatitis • • • • • Wet dressings Topical corticosteroids, pimecrolimus, tacrolimus Oral corticosteroids, oral antibiotics Discard old socks worn in culprit shoes Treat hyperhidrosis: zeasorb powder, aluminum chloride, Drionic unit, botulinum toxin, tea foot baths • Patch testing and allergen avoidance DRIONIC for Hyperhidrosis Online price $140 Tea Foot Baths to Reduce Hyperhidrosis • Boil 6 to 8 tea bags in 1 quart of water for 10 minutes • Place in basin and allow to cool to lukewarm temperature • Soak feet for 30 minutes once to twice daily • After 1 to 2 weeks can reduce frequency • Stains skin and toenails Management of Shoe Dermatitis American Contact Dermatitis Society • Web site for members provides listings of companies that make hypoallergenic shoes including vegetable tanned leather shoes, wooden clogs, plastic shoes • L.L.Bean has shoes with sheepskin insoles stitched to leather sole • “Jellies” sandals are made of rubber‐free plastic • Birkenstock sandals are made of cork and latex DYSHIDROSIS TINEA PEDIS DYSHIDROSIS TINEA PEDIS Dyshidrosis or Pompholyx? Lofgren and Warshaw Dermatitis 2006;17:165‐181 • Dyshidrosis: chronic recurrent eruption of 1‐2 mm vesicles on palms, soles, and/or lateral aspects of fingers • Pompholyx: rare explosive onset of large bullae on hands Causes of Dyshidrosis Lofgren and Warshaw Dermatitis 2006;17:165‐181 Guillet et al Arch Dermatol 2007;143:1504‐1508 • • • • • • • Allergens Irritants Dermatophytid Intravenous immunoglobulin therapy Hyperhidrosis Atopy Smoking Allergens as a Cause of Dyshidrosis Guillet et al Arch Dermatol 2007;143:1504‐1508 • 120 pts with dyshidrosis seen during a 3 year period • 70% had hand involvement only, 10% foot involvement only, 20% both hand and foot • 81 of 120 pts with dyshidrosis had allergic contact dermatitis • Hygiene product most common cause of allergy usually related to fragrance and Balsam of Peru • Metal was the second most common cause of allergy with positive reactions to nickel, chromium, cobalt – only 2 of 30 metal positive pts flared with oral nickel and cobalt challenge Dietary Treatment of Dyshidrosis AVOID THESE HIGH COBALT FOODS • • • • • • • • • • • Apricots Beans Beer Beets Cabbage Cloves Cocoa, chocolate, coffe, tea Liver Nuts Scallops Whole grain flour AVOID THESE HIGH NICKEL FOODS • • • • • • • • • • • • • All canned foods or foods cooked with Ni‐containing pots, utensils Asparagus Beans Broccoli Carrots Corn Lettuce Lentils Mushrooms Cocoa, chocolate, coffee, tea Sunflower and sesame seeds, nuts Herring, shrimp, oysters Whole wheat flour, bran, oatmeal Therapeutic Ladder for Dyshidrosis • STOP SMOKING • Dry skin care • Avoidance of irritants and allergens • Wear dry cotton socks and white cotton gloves under vinyl • Antihistamines • Soaks of dilute vinegar, aluminum acetate, potassium permanganate • Topical steroids, pimecrolimus, tacrolimus • • • • • Treatment for hyperhidrosis Oral steroids Phototherapy Systemic tx: – MTX – Azathioprine – Mycophenolate mofetil – Cyclosporine Low nickel, low cobalt diet Hand and Foot Psoriasis • Affects 1/3 of patients with psoriasis • Many patients have only acral psoriasis without psoriasis elsewhere • Often associated with psoriatic arthritis • Patients have diminished quality of life related to physical limitations and pain • Often treatment resistant • May mimic frictional hand eczema, contact dermatitis, dyshidrosis, tinea PSORIASIS TINEA PSORIASIS TINEA Psoriasis Tinea in Pt with Psoriasis Palmoplantar pustulosis Dyshidrosis Variants of Palmoplantar Psoriasis Plaque Variants of Palmoplantar Psoriasis Hyperkeratotic with Fissures Variants of Palmoplantar Psoriasis Palmoplantar pustulosis Acrodermatitis Continua Jo et al: J Dermatology 2006;33:787‐91 Palmoplantar Pustulosis • Associated with autoimmune • Sterile pusutles and thyroid disease, celiac disease, erythematous plaques on tobacco use, type2 DM palms and soles • Women affected 3 times more • Exacerbated by stress, metal allergies, focal infection commonly than men (tonsillitis), manual trauma • Usually begins in 5th and 6th • May be associated with decades SAPHO syndrome (synovitis, • Approximately 20% of pts have acne, pustulosis, hyperostosis, psoriasis affecting other sites osteitis) especially affecting • Does not share gene locus anterior chest wall strongly associated with • May develop as paradoxical psoriasis vulgaris and guttate reaction to anti‐TNF therapy psoriasis • Some experts consider PPP to be a different entity than pustular psoriasis Generalized Pustular Psoriasis Therapeutic Ladder for Palmoplantar Psoriasis • STOP SMOKING • Topical therapy – Tar soaks – Ultrapotent topical steroid cream qAM and ointment qhs – Cover ointments with wet cotton gloves or socks and then wrap with plastic for 2 hours then follow with emollient cream – Vitamin D analogs – Tazarotene qhs and topical steroid qAM – Urea, Salicylic acid lotion • Phototherapy – NB‐UVB Hand and Foot – Excimer laser – Topical PUVA • Systemic therapy – – – – – Acitretin Re‐PUVA MTX Cyclosporine Biologics • Miscellaneous tx’s reported for PPP – Colchicine – Itraconazole – Tetracycline Phototherapy Excimer Laser 308 nm Excimer Therapy Han et al: Photodermatology, Photoimmunology, & Photomedicine 2008;24:231‐6 25 treatments once weekly 308 nm Excimer Therapy Nistico et al: JEADV 2006:20; 523‐526 44 of 54 pts with palmoplantar psoriasis had 75% improvement after an average of 10 treatments for palms and 13 for soles with benefit maintained at 16 week followup Traditional Systemic Psoriasis Therapies Drug Pros Cons MTX Gold standard tx for skin and Risk for hepatotoxicity, bone joints; low cost:$1,000/year for 25 marrow suppression, multiple mg qwk plus labs drug interactions; caution with renal impairment; frequent lab monitoring and periodic liver bx; abortifacient Cys A (Neoral) Rapid improvement of labile psoriasis; can help joints Risk for immunosuppression, htn, nephrotoxicity, hyperlipidemia, multiple drug interactions,hypertrichosis; frequent laboratory monitoring; high cost: $6,000‐7,800/year for 300 mg qd plus labs Acitretin (Soriatane) Rapid improvement of pustular psoriasis; high efficacy for palmoplantar disease; no immunosuppression Risk for hyperlipidemia, hepatotoxicity, dry skin and mucous membranes, alopecia; teratogen; periodic laboratory monitoring; no benefit for joints; high cost: $9,000/year for 25 mg qd plus labs Biologics for Psoriasis Drug Positives Negatives Infliximab (Remicade) High efficacy for skin and joints; infrequent tx (wk 0,2,6,then q6-8 wks); wt based dosing; rapid clearing by 2nd or 3rd tx; infrequent lab monitoring IV infusion at infusion center; risk for infusion rks;greatest risk for immunosuppression; hepatotoxicity ; exclusion criteria:MS,CHF; $2030,000/year Adalimumab (Humira) High efficacy for skin and joints; qowk SC injection; rapid significant response by wk 4;infrequent lab monitoring Risk for immunosuppression; exclusion criteria: MS, CHF;$20,000/year Etanercept (Enbrel) High efficacy for skin and joints; once or twice weekly SC injection; improvement within 1-3 mos; recent successful trial for children and adolescents with psoriasis;infrequent lab monitoring Risk for immunosuppression; exclusion criteria:MS, CHF; some pts require continued twice wkly tx;$17-34,000/year Ustekinumab (Stelara) High efficacy for skin; rapid clearing by wk 12; in trial for joint disease; infrequent SC tx (wk 0, 4, then q12 wks);no restriction for MS pts; wt based dosing SC injection by nurse at physician’s office or at pt’s home; Risk for immunosuppression; $23-46,000/year Efalizumab for Palmoplantar Psoriasis Wozel et al: Acta Dermatovenerol Alp Panonica Adriat 2008 3:133‐6 Efalizumab (Raptiva) Pulled From Market • Monoclonal antibody against CD11a • Prevents T‐lymphocyte activation, migration, and reactivation • 2003: approved for treatment of moderate to severe plaque psoriasis • Found niche in treating hand and foot psoriasis with one study showing 33% of efalizumab treated patients achieving Physician Global Assessment of clear/nearly clear • 2008 USA: 2 cases of progressive multifocal leukoencephalopathy (> 70 y/o) led to death; efalizumab as monotherapy for > 3 years • Feb 2009: 3rd case identified in Germany (47 y/o); efalizumab as monotherapy for > 3 years • 4th pt with progressive neurologic symptoms died of unknown cause • April 8, 2009 Genentech announced phased voluntary withdrawal of efalizumab from US market PALMOPLANTAR PSORIASIS Successful treatment with infliximab DiLernia and Guareschi: Dermatol Online J 2010;16:8 Leonardi et al: Arch Dermatol Published on line Dec 2010 49 pts treated with adalimumab and 23 pts treated with placebo for 16 weeks At 16 weeks, 31% (15 of 49) of adalimumab pts and 4% (1 of 23) of placebo pts achieved a Physician’s Global Assessment of clear/almost clear TNF‐α Inhibitor Induced Psoriasis • More than 120 cases described in the literature • Strong predilection for development of palmoplantar pustulosis • Most pts were receiving treatment for an indication other than psoriasis (rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease) • Most pts were able to continue treatment with the anti‐TNF and add topical therapy for the psoriasis; some pts switched to an alternative anti‐TNF with good results DON’T FORGET TO THINK ABOUT ZEBRAS Dyshidrosiform Immunobullous Disease Kim et al. Dyshidrosiform Bullous Pemphigoid: Acta Derm Venereol 2004;84:253‐4 CTCL of Palms and Soles Responsive to topical PUVA Spieth et al: Dermatology 2002; 205:239‐244 BUT REMEMBER—COMMON THINGS HAPPEN COMMONLY Pt with CTCL, Shoe Dermatitis, and Id Reaction
Similar documents
Spongiotic and psoriasiform reaction pattern
Acute self limited disease F>M 15-55 years (about 75% of patients) Seasonal variations Recurrent disease in < 5%
More information